REG - Arecor Therapeutics - Arecor Granted Key U.S Patent

Arecor TherapeuticsAnnouncement

23/03/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220323:nRSW6673Fa&default-theme=true

RNS Number : 6673F  Arecor Therapeutics PLC  23 March 2022

Arecor Therapeutics plc

("Arecor" or the "Group")

 

ARECOR GRANTED KEY U.S. PATENT PROTECTING PROPRIETARY INSULIN PRODUCTS

 

Further strengthens the Company's extensive patent portfolio protecting its
proprietary Arestat™ technology and diabetes product portfolio

 

Cambridge, UK, 23 March 2022: Arecor Therapeutics plc (AIM: AREC), the
biopharmaceutical group advancing today's therapies to enable healthier lives,
is pleased to announce that the United States Patent and Trademark Office has
granted a patent (US11278624) protecting novel formulations of the Group's
proprietary insulin products, AT247 and AT278.

 

Dr Jan Jezek, Chief Scientific Officer at Arecor, commented: "Arecor's novel
insulin products, based on a combination of existing insulin analogues and our
highly innovative formulation science, have potential to improve convenience,
compliance and enable more effective management of blood glucose for people
living with type 1 and type 2 diabetes. As the clinical validation of the
superiority of these products compared to current gold standard prandial
insulins continues, we are also advancing the intellectual property protection
for these products. This recently granted US patent, the first within the
Group's comprehensive insulin IP strategy, is a significant milestone, and we
will continue to strengthen our IP portfolio with additional patent
applications already in progress."

 

Arecor has invested in building a strong patent portfolio to protect the
Arestat™ technology platform and its proprietary pipeline products. The
Group's intellectual property (IP) portfolio currently comprises 36 patent
families, including >50 granted patents in Europe, the US and in other key
territories.  As part of this strategy, Arecor has robust IP directed to the
novel insulin compositions that protect different aspects of AT247 and AT278
formulations, as well as their specific properties and methods of use.
Arecor's strategy is to generate a fortress of both narrow and broad
interrelated IP rights that cover the features of these products. US11278624
is the first granted US patent within the Group's comprehensive insulin IP
strategy.

 

-ENDS-

 

 

For more information, please contact:

 Arecor Therapeutics plc                          www.arecor.com (http://www.arecor.com/)
 Dr Sarah Howell, Chief Executive Officer         Tel: +44 (0) 1223 426060

                                                  Email: info@arecor.com (mailto:sarah.howell@arecor.com)

 Susan Lowther, Chief Financial Officer           Tel: +44 (0) 1223 426060

                                                  Email: info@arecor.com (mailto:info@arecor.com)

 Mo Noonan, Communications                        Tel: +44 (0) 7876 444977

                                                  Email: mo.noonan@arecor.com (mailto:mo.noonan@arecor.com)

 Panmure Gordon (UK) Limited (NOMAD and Broker)   Tel: +44 (0) 20 7886 2500

 Freddy Crossley, Emma Earl (Corporate Finance)

 Rupert Dearden (Corporate Broking)

 Consilium Strategic Communications
 Chris Gardner, David Daley, Angela Gray          Tel: +44 (0) 20 3709 5700

                                                  Email: arecor@consilium-comms.com (mailto:arecor@consilium-comms.com)

 

Notes to Editors

 

About Arecor

Arecor Therapeutics plc is a globally focused biopharmaceutical company
transforming patient care by bringing innovative medicines to market through
the enhancement of existing therapeutic products. By applying our innovative
proprietary formulation technology platform, Arestat™, we are developing an
internal portfolio of proprietary products in diabetes and other indications,
as well as working with leading pharmaceutical and biotechnology companies to
deliver enhanced formulations of their therapeutic products. The Arestat™
platform is supported by an extensive patent portfolio.

 

For further details please see our website, www.arecor.com
(http://www.arecor.com)

 

 

About Arestat™

The Arestat™ technology enables superior product profiles across a broad
range of therapies, including various types of biopharmaceuticals and
specialty hospital products. In addition to its internal portfolio of superior
proprietary products in diabetes and other indications, Arecor leverages the
Arestat™ technology in partnerships with leading pharmaceutical and
biotechnology companies to deliver enhanced formulations of their therapeutic
products under a technology licensing model.

 

 

About AT247

AT247 is an ultra-rapid insulin that aims to accelerate insulin absorption,
post injection, to enable more effective management of blood glucose levels
for people living with diabetes, particularly around difficult to manage
mealtimes.  Early clinical evidence suggests that AT247 may facilitate a
fully closed loop artificial pancreas, a potentially life changing treatment
option for people living with diabetes, and a US Phase I clinical trial is
currently underway investigating the potential of the product when delivered
by continuous subcutaneous infusion via insulin pump.

 

About AT278

AT278 is Arecor's ultra-concentrated, ultra-rapid acting insulin designed to
accelerate the absorption of insulin post injection, to enable more effective
management of blood glucose levels to the increasing number of people with
diabetes with high daily insulin requirements (>200 units/day), whilst
maintaining the convenience and compliance benefits of being able to deliver
these high insulin doses in a lower injection volume via a single injection.
A truly rapid acting concentrated insulin is a critical step towards the
advancement and miniaturisation of the next generation of insulin delivery
devices.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCJTMRTMTITBFT